CNSX:RLSC

Stock Analysis Report

Executive Summary

RISE Life Science Corp. engages in developing and evolving medical and adult hemp-based formulations to create general use health and well-being products for the consumer category in the United States.

Snowflake

Fundamentals

Weak fundamentals or lack of information.


Similar Companies

Share Price & News

How has RISE Life Science's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-28.6%

RLSC

-10.0%

CA Pharmaceuticals

-0.3%

CA Market


1 Year Return

-66.7%

RLSC

-62.2%

CA Pharmaceuticals

0.9%

CA Market

Return vs Industry: RLSC underperformed the Canadian Pharmaceuticals industry which returned -62.2% over the past year.

Return vs Market: RLSC underperformed the Canadian Market which returned 0.9% over the past year.


Share holder returns

RLSCIndustryMarket
7 Day-28.6%-10.0%-0.3%
30 Day-37.5%-26.9%-2.1%
90 Day-70.6%-35.3%-1.5%
1 Year-66.7%-66.7%-62.2%-62.2%4.4%0.9%
3 Year-83.3%-83.3%84.7%83.3%15.7%5.4%
5 Year-98.8%-98.8%269.8%269.8%26.1%7.9%

Price Volatility Vs. Market

How volatile is RISE Life Science's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is RISE Life Science undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether RISE Life Science is trading at an attractive price based on the cash flow it is expected to produce in the future. But as RISE Life Science has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is RISE Life Science expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

92.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as RISE Life Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has RISE Life Science performed over the past 5 years?

-39.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: RLSC is unprofitable, and losses have increased over the past 5 years at a rate of -39.1% per year.

Accelerating Growth: Unable to compare RLSC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RLSC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.6%).


Return on Equity

High ROE: RLSC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: RLSC is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: RLSC is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is RISE Life Science's financial position?


Financial Position Analysis

Short Term Liabilities: RLSC has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: RLSC has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: RLSC has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: RLSC's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: RLSC has a low level of unsold assets or inventory.

Debt Coverage by Assets: RLSC has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RLSC has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: RLSC has less than a year of cash runway if free cash flow continues to reduce at historical rates of -84.5% each year


Next Steps

Dividend

What is RISE Life Science's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%6.0%industryaverage2.3%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate RLSC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate RLSC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if RLSC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RLSC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RLSC's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

  • Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

What is the CEO of RISE Life Science's salary, the management and board of directors tenure and is there insider trading?

1.0yrs

Average management tenure


CEO

Scott Secord 0

0.5yrs

Tenure

CA$685,240

Compensation

Mr. Scott Lawrence Secord has been an Executive Chairman of RISE Life Science Corp. since October 2, 2018 and as its Interim Chief Executive Officer since April 30, 2019. He served as the Chief Executive O ...


CEO Compensation Analysis

Compensation vs. Market: Scott has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the Canadian market.

Compensation vs Earnings: Insufficient data to compare Scott's compensation with company performance.


Management Age and Tenure

1.0yrs

Average Tenure

Experienced Management: RLSC's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Age and Tenure

3.0yrs

Average Tenure

Experienced Board: RLSC's board of directors are considered experienced (3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyCA$12,75707 Feb 19
Scott Secord
EntityIndividual
Role
Chief Executive Officer
Executive Chairman & Interim CEO
Shares45,000
Max PriceCA$0.29
BuyCA$2,50001 Feb 19
Scott Secord
EntityIndividual
Role
Chief Executive Officer
Executive Chairman & Interim CEO
Shares10,000
Max PriceCA$0.25
BuyCA$16,19529 Jan 19
Scott Secord
EntityIndividual
Role
Chief Executive Officer
Executive Chairman & Interim CEO
Shares79,000
Max PriceCA$0.20
BuyCA$6,31514 Dec 18
Scott Secord
EntityIndividual
Role
Chief Executive Officer
Executive Chairman & Interim CEO
Shares42,500
Max PriceCA$0.16
BuyCA$7,25011 Dec 18
Scott Secord
EntityIndividual
Role
Chief Executive Officer
Executive Chairman & Interim CEO
Shares50,000
Max PriceCA$0.15

Ownership Breakdown


Management Team

  • John Maynard

    Consultant of Scout DS Technology

    • Tenure: 0yrs
  • Chris Moreau

    Consultant

    • Tenure: 3.5yrs
    • Compensation: CA$50.74k
  • Sandra Benson

    Manager of Investor Relations

    • Tenure: 0yrs
  • Scott Secord

    Executive Chairman & Interim CEO

    • Tenure: 0.5yrs
    • Compensation: CA$685.24k
  • Robert Lelovic

    Chief Financial Officer

    • Tenure: 1.7yrs
    • Compensation: CA$244.53k
  • Mike Kish

    Vice President of Sales

    • Tenure: 0yrs
  • James Overbeck

    Engineering Consultant

    • Tenure: 0yrs
  • Anton Mattadeen

    Consultant

    • Tenure: 1yrs
    • Compensation: CA$256.10k
  • Chris Dollard

    Consultant

    • Tenure: 1yrs
    • Compensation: CA$275.27k
  • Andy DangVu

    Chief Product Specialist

    • Tenure: 0yrs

Board Members

  • Michael Campbell

    Director

    • Tenure: 1.7yrs
    • Compensation: CA$220.03k
  • Ashwath Mehra (54yo)

    Director

    • Tenure: 3.7yrs
    • Compensation: CA$131.10k
  • Isabella Caniggia

    Member of Scientific Advisory Board

    • Tenure: 10.7yrs
  • Scott Secord

    Executive Chairman & Interim CEO

    • Tenure: 0.5yrs
    • Compensation: CA$685.24k
  • Greg Mills (57yo)

    Director

    • Tenure: 0.8yrs
  • G.B. Mancini

    Member of The Prevu Medical Advisory Board

    • Tenure: 0yrs
  • Henry Solomon

    Member of Prevu Medical Advisory Board

    • Tenure: 7.7yrs
  • Milan Gupta

    Member of Prevu Medical Advisory Board

    • Tenure: 0yrs
  • Alain Sotto

    Member of The Scout DS(R) Medical Advisory Board

    • Tenure: 4.6yrs
  • Edward Hillhouse

    Chairman of Medical Scientific Advisory Board

    • Tenure: 2.4yrs

Company Information

RISE Life Science Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: RISE Life Science Corp.
  • Ticker: RLSC
  • Exchange: CNSX
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$3.015m
  • Shares outstanding: 60.30m
  • Website: https://riselifescience.com

Location

  • RISE Life Science Corp.
  • 145 King Street West
  • Suite 210
  • Toronto
  • Ontario
  • M5H IJ8
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MCUI.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDSep 2002
RLSCCNSX (Canadian National Stock Exchange)YesCommon SharesCACADSep 2002
L02DB (Deutsche Boerse AG)YesCommon SharesDEEURSep 2002

Biography

RISE Life Science Corp. engages in developing and evolving medical and adult hemp-based formulations to create general use health and well-being products for the consumer category in the United States. It  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 03:09
End of Day Share Price2019/10/10 00:00
Earnings2019/05/31
Annual Earnings2018/11/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)